CRISPR Therapeutics AG Files 8-K for Officer/Director Changes
Ticker: CRSP · Form: 8-K · Filed: Mar 26, 2025 · CIK: 1674416
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: CRSP
TL;DR
CRISPR Therapeutics filed an 8-K detailing board and exec comp changes. No major financial news.
AI Summary
CRISPR Therapeutics AG announced on March 24, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel. This report is filed under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns corporate governance and executive appointments, not significant financial events or operational risks.
Key Players & Entities
- CRISPR Therapeutics AG (company) — Registrant
- March 24, 2025 (date) — Date of earliest event reported
- 41 (0)41 561 32 77 (phone_number) — Registrant's telephone number
FAQ
What specific items are covered in this 8-K filing by CRISPR Therapeutics AG?
This 8-K filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is CRISPR Therapeutics AG.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on March 24, 2025.
What is the principal executive office address of CRISPR Therapeutics AG?
The principal executive office address is Baarerstrasse 14, 6300 Zug, Switzerland.
Under which section of the Securities Exchange Act is this Current Report filed?
This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 26, 2025 regarding CRISPR Therapeutics AG (CRSP).